<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA + Metastatic Colorectal Cancers</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Chengcheng</forename><surname>Zhang</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Center of Biotherapy</orgName>
								<orgName type="institution" key="instit1">Southwest Hospital</orgName>
								<orgName type="institution" key="instit2">Third Military Medical University</orgName>
								<address>
									<postCode>400038</postCode>
									<settlement>Chongqing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Institute of Hepatobiliary Surgery</orgName>
								<orgName type="institution" key="instit1">Southwest Hospital</orgName>
								<orgName type="institution" key="instit2">Third Military Medical University</orgName>
								<address>
									<postCode>400038</postCode>
									<settlement>Chongqing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Zhe</forename><surname>Wang</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Oncology</orgName>
								<orgName type="institution" key="instit1">Southwest Hospital</orgName>
								<orgName type="institution" key="instit2">Third Military Medical University</orgName>
								<address>
									<postCode>400038</postCode>
									<settlement>Chongqing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Zhi</forename><surname>Yang</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Center of Biotherapy</orgName>
								<orgName type="institution" key="instit1">Southwest Hospital</orgName>
								<orgName type="institution" key="instit2">Third Military Medical University</orgName>
								<address>
									<postCode>400038</postCode>
									<settlement>Chongqing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Meiling</forename><surname>Wang</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Center of Biotherapy</orgName>
								<orgName type="institution" key="instit1">Southwest Hospital</orgName>
								<orgName type="institution" key="instit2">Third Military Medical University</orgName>
								<address>
									<postCode>400038</postCode>
									<settlement>Chongqing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Shiqi</forename><surname>Li</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yunyan</forename><surname>Li</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Center of Biotherapy</orgName>
								<orgName type="institution" key="instit1">Southwest Hospital</orgName>
								<orgName type="institution" key="instit2">Third Military Medical University</orgName>
								<address>
									<postCode>400038</postCode>
									<settlement>Chongqing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Rui</forename><surname>Zhang</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Center of Biotherapy</orgName>
								<orgName type="institution" key="instit1">Southwest Hospital</orgName>
								<orgName type="institution" key="instit2">Third Military Medical University</orgName>
								<address>
									<postCode>400038</postCode>
									<settlement>Chongqing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Zhouxing</forename><surname>Xiong</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Center of Biotherapy</orgName>
								<orgName type="institution" key="instit1">Southwest Hospital</orgName>
								<orgName type="institution" key="instit2">Third Military Medical University</orgName>
								<address>
									<postCode>400038</postCode>
									<settlement>Chongqing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Zhihao</forename><surname>Wei</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Center of Biotherapy</orgName>
								<orgName type="institution" key="instit1">Southwest Hospital</orgName>
								<orgName type="institution" key="instit2">Third Military Medical University</orgName>
								<address>
									<postCode>400038</postCode>
									<settlement>Chongqing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Junjie</forename><surname>Shen</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Center of Biotherapy</orgName>
								<orgName type="institution" key="instit1">Southwest Hospital</orgName>
								<orgName type="institution" key="instit2">Third Military Medical University</orgName>
								<address>
									<postCode>400038</postCode>
									<settlement>Chongqing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Yongli</forename><surname>Luo</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Center of Biotherapy</orgName>
								<orgName type="institution" key="instit1">Southwest Hospital</orgName>
								<orgName type="institution" key="instit2">Third Military Medical University</orgName>
								<address>
									<postCode>400038</postCode>
									<settlement>Chongqing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Qianzhen</forename><surname>Zhang</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Limei</forename><surname>Liu</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Center of Biotherapy</orgName>
								<orgName type="institution" key="instit1">Southwest Hospital</orgName>
								<orgName type="institution" key="instit2">Third Military Medical University</orgName>
								<address>
									<postCode>400038</postCode>
									<settlement>Chongqing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department">Department of Pathology</orgName>
								<orgName type="institution" key="instit1">Southwest Hospital</orgName>
								<orgName type="institution" key="instit2">Third Military Medical University</orgName>
								<address>
									<postCode>400038</postCode>
									<settlement>Chongqing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hong</forename><surname>Qin</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Center of Biotherapy</orgName>
								<orgName type="institution" key="instit1">Southwest Hospital</orgName>
								<orgName type="institution" key="instit2">Third Military Medical University</orgName>
								<address>
									<postCode>400038</postCode>
									<settlement>Chongqing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Department of Oncology</orgName>
								<orgName type="institution" key="instit1">The Second Affiliated Hospital</orgName>
								<orgName type="institution" key="instit2">Chongqing Medical University</orgName>
								<address>
									<postCode>400016</postCode>
									<settlement>Chongqing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Wei</forename><surname>Liu</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Center of Biotherapy</orgName>
								<orgName type="institution" key="instit1">Southwest Hospital</orgName>
								<orgName type="institution" key="instit2">Third Military Medical University</orgName>
								<address>
									<postCode>400038</postCode>
									<settlement>Chongqing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Institute of Hepatobiliary Surgery</orgName>
								<orgName type="institution" key="instit1">Southwest Hospital</orgName>
								<orgName type="institution" key="instit2">Third Military Medical University</orgName>
								<address>
									<postCode>400038</postCode>
									<settlement>Chongqing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Feng</forename><surname>Wu</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Pathology</orgName>
								<orgName type="institution" key="instit1">Southwest Hospital</orgName>
								<orgName type="institution" key="instit2">Third Military Medical University</orgName>
								<address>
									<postCode>400038</postCode>
									<settlement>Chongqing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Wei</forename><surname>Chen</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Radiology</orgName>
								<orgName type="institution">Southwest Hospital</orgName>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="institution">Third Military Medical University</orgName>
								<address>
									<postCode>400038</postCode>
									<settlement>Chongqing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Feng</forename><surname>Pan</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Oncology</orgName>
								<orgName type="institution" key="instit1">Southwest Hospital</orgName>
								<orgName type="institution" key="instit2">Third Military Medical University</orgName>
								<address>
									<postCode>400038</postCode>
									<settlement>Chongqing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Xianquan</forename><surname>Zhang</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Oncology</orgName>
								<orgName type="institution" key="instit1">The Second Affiliated Hospital</orgName>
								<orgName type="institution" key="instit2">Chongqing Medical University</orgName>
								<address>
									<postCode>400016</postCode>
									<settlement>Chongqing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ping</forename><surname>Bie</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Institute of Hepatobiliary Surgery</orgName>
								<orgName type="institution" key="instit1">Southwest Hospital</orgName>
								<orgName type="institution" key="instit2">Third Military Medical University</orgName>
								<address>
									<postCode>400038</postCode>
									<settlement>Chongqing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Houjie</forename><surname>Liang</surname></persName>
							<email>lianghoujie@sina.com</email>
							<affiliation key="aff2">
								<orgName type="department">Department of Oncology</orgName>
								<orgName type="institution" key="instit1">Southwest Hospital</orgName>
								<orgName type="institution" key="instit2">Third Military Medical University</orgName>
								<address>
									<postCode>400038</postCode>
									<settlement>Chongqing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gabriele</forename><surname>Pecher</surname></persName>
							<email>gabriele.pecher@charite.de</email>
							<affiliation key="aff7">
								<orgName type="department">Medical Clinic of Hematology, Oncology and Tumor Immunology</orgName>
								<orgName type="institution" key="instit1">CCM</orgName>
								<orgName type="institution" key="instit2">Charité-University Medicine Berlin</orgName>
								<address>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Cheng</forename><surname>Qian</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Center of Biotherapy</orgName>
								<orgName type="institution" key="instit1">Southwest Hospital</orgName>
								<orgName type="institution" key="instit2">Third Military Medical University</orgName>
								<address>
									<postCode>400038</postCode>
									<settlement>Chongqing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff8">
								<orgName type="department">Center of Biotherapy</orgName>
								<orgName type="institution" key="instit1">Southwest Hospital</orgName>
								<orgName type="institution" key="instit2">Third Military Medical University</orgName>
								<address>
									<postCode>400038</postCode>
									<settlement>Chongqing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff9">
								<orgName type="department" key="dep1">Medical Clinic of Hematology, Oncology and Tumor Immu-nology</orgName>
								<orgName type="department" key="dep2">CCM</orgName>
								<orgName type="institution">Charité-University Medicine Berlin</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff10">
								<orgName type="department">Department of Oncology</orgName>
								<orgName type="institution" key="instit1">Southwest Hospital</orgName>
								<orgName type="institution" key="instit2">Third Military Medical University</orgName>
								<address>
									<postCode>400038</postCode>
									<settlement>Chongqing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA + Metastatic Colorectal Cancers</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">B139F660FAD0504599C8FF06FEE58085</idno>
					<idno type="DOI">10.1016/j.ymthe.2017.03.010</idno>
					<note type="submission">Received 11 January 2017; accepted 5 March 2017;</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:31+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Chimeric antigen receptor T (CAR-T) cells have shown promising efficacy in treatment of hematological malignancies, but its applications in solid tumors need further exploration.</s><s>In this study, we investigated CAR-T therapy targeting carcino-embryonic antigen (CEA)-positive colorectal cancer (CRC) patients with metastases to evaluate its safety and efficacy.</s><s>Five escalating dose levels (DLs) (1 Â 10 5 to 1 Â 10 8 /CAR + /kg cells) of CAR-T were applied in 10 CRC patients.</s><s>Our data showed that severe adverse events related to CAR-T therapy were not observed.</s><s>Of the 10 patients, 7 patients who experienced progressive disease (PD) in previous treatments had stable disease after CAR-T therapy.</s><s>Two patients remained with stable disease for more than 30 weeks, and two patients showed tumor shrinkage by positron emission tomography (PET)/computed tomography (CT) and MRI analysis, respectively.</s><s>Decline of serum CEA level was apparent in most patients even in long-term observation.</s><s>Furthermore, we observed persistence of CAR-T cells in peripheral blood of patients receiving high doses of CAR-T therapy.</s><s>Importantly, we observed CAR-T cell proliferation especially in patients after a second CAR-T therapy.</s><s>Taken together, we demonstrated that CEA CAR-T cell therapy was well tolerated in CEA + CRC patients even in high doses, and some efficacy was observed in most of the treated patients.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p><s>Adoptive T cell immunotherapy has been regarded as a promising antitumor treatment.</s><s>Genetically modified T cells that express chimeric antigen receptors (CARs) eliminate tumor cells by binding to tumor antigens through antigen-antibody recognition.</s><s>These chimeric antigen receptor T (CAR-T) cells recognize tumor cells directly without the process of antigen presentation and major histocompatibility complex (MHC) restriction.</s><s>CAR-T therapy has been widely shown to have a promising antitumor effect and a high complete remission (CR) rate in CD19 + hematological malignancies. <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b1">2</ref></s><s>4]<ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref> Although some efficacies were observed in some studies including complete regression of a single glioblastoma case treated with multiple infusions of IL-13Ra2 CAR-T cells, the general outcome of CAR-T cell therapy for solid tumors was not satisfactory in many studies.</s><s>In addition, on-target/ off-tumor toxicities were observed in some studies. <ref type="bibr" target="#b7">8,</ref><ref type="bibr" target="#b8">9</ref></s><s>Therefore, more clinical trials with improvement of CAR-T technologies are needed to improve its safety and efficacy.</s></p><p><s>CEA is a sensitive tumor biomarker for gastrointestinal cancer, and it is widely expressed in colorectal cancer (CRC) tissue and serum.</s><s>Moreover, CEA expression cannot be detected in most normal adult tissues, except in the gastrointestinal tract at a low level restricted to the apical surface of the epithelial cell membranes facing the lumen, which is invisible to immune cells. <ref type="bibr" target="#b9">10</ref></s><s>Thus, it makes CEA a potent target for CAR-T therapy.</s><s>CAR-T therapy targeting CEA was first reported through the hepatic artery infusion of CAR-T cells. <ref type="bibr" target="#b6">7</ref></s><s>Importantly, safety of CAR-T therapy through local delivery was confirmed.</s><s>However, five of six patients still experienced progressive disease after treatment using CAR-T cells.</s></p><p><s>In this study, we carried out a phase I clinical trial of CEA CAR-T therapy of CEA + CRC patients by systemic delivery through intravenous infusion (NCT02349724).</s><s>To improve the efficacy of CAR-T therapy, we used lymphodepletion before CAR-T cell infusion.</s><s>Ten relapsed and refractory CRC patients with metastasis were enrolled.</s><s>Four patients had received two infusions with different doses.</s><s>To ensure safety, we adopted an escalating dose with five dose levels (DLs).</s><s>Our CEA CAR-T cell therapy was well tolerated in CEA + CRC patients even at high doses, and some efficacy was observed in most of the treated patients.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Characteristics of CAR-T Cells</head><p><s>The manufacture period for CAR-T products was approximately 2 weeks, and the cell products were comprehensively measured by flow cytometry (FCM) on the day before infusion (Figure <ref type="figure" target="#fig_0">1A</ref>).</s><s>CD3 + (T cells; median, 94.6%; range, 92.2%-98.4%),</s><s>CD16 + CD56 + (NK cells; median, 3.4%; range, 0.5%-5.6%),</s><s>CD3 + CD16 + CD56 + (NKT cells; median, 15.1%; range, 8.2%-24.5%),</s><s>and CAR + % (median, 33.7%; range, 14.7%-43.2%)</s><s>subsets were present (Figure <ref type="figure" target="#fig_0">1B</ref>).</s><s>The proportion of CD4/8 in CAR + products (median, 0.4; range, 0.3-0.7)</s><s>showed no difference compared with that in the CD3 + product (median, 0.2; range, 0.1-0.5)</s><s>(Figure <ref type="figure" target="#fig_0">1C</ref>).</s><s>Memory T cells contained several subtypes, and we selected CD3, CD45RA, CD45RO, and CD62L as markers for classification. <ref type="bibr" target="#b10">11</ref></s><s>Proportion of T naive (Tn; CD3 + /CD45RA + /RO À /CD62L + ; median, 6.1%; range, 1.6%-18.3%),</s><s>T central memory (Tcm; CD3 + /CD45RA À /RO + / CD62L + ; median, 9.9%; range, 5.6%-36.7%),</s><s>and T effector memory Between the completion of lymphodepletion and initiation of CAR-T infusion, blood tests were administered on day 0 to reconfirm whether the patient could tolerate cell infusion.</s><s>CAR-T infusion was executed on days 1, 2, and 3, and 10%, 30%, and 60% of the total cell dose were administrated, respectively.</s><s>(B-E) Characteristics of CAR-T cells were analyzed by FCM results for quality control of the CAR-T cell products.</s><s>For each product, the ratios of T cells, NK cells, NKT cells, and CAR-T cells were measured before infusion.</s><s>There was no difference in CD4/8 between CAR + cells and CD3 + cells.</s><s>Tm cells and checkpoint inhibitors were also detected.</s><s>E, enrollment.</s></p><p><s>(Tem; CD3 + /CD45RA À /RO + /CD62L À ; median, 24.4%; range, 16.1%-43.4%)</s><s>cells were shown (Figure <ref type="figure" target="#fig_0">1D</ref>).</s><s>Checkpoint inhibitors were also measured in CAR-T products.</s><s>Programmed death 1 (PD-1) expression was not detected on the surface of CD4 + and CD8 + cells.</s><s>LAG-3 was expressed only in CD8 + cells (median, 14.7%; range, 7.1%-31.3%).</s><s>TIM-3 was expressed in both CD4 + (median, 14.5%; range, 5.8%-16.5%)</s><s>and CD8 + (median, 75.8%; range, 49.2%-78.6%)</s><s>(Figure <ref type="figure" target="#fig_0">1E</ref>).</s><s>In the cytotoxicity assay, CEA CAR-T cells specifically targeting CEA high-expression tumor cells (LoVo and LS174T), CEA medium-expression tumor cells (HT-29), and CEA low-expression tumor cells (MCF7) were confirmed (Figure <ref type="figure" target="#fig_0">S1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adverse Events after CAR-T Therapy</head><p><s>We recorded adverse events and did not observe any CAR-T-related severe events (Table <ref type="table" target="#tab_0">S1</ref>).</s><s>For patients receiving DL5, patient (P) 9 tolerated the treatment well, but P7 and P10 had a fever of 39 C to 40 C within a few hours after cell infusion.</s><s>P7 had a body temperature of 40 C on day 3 that lasted for 2 days discontinuously.</s><s>P10 had a fever after each infusion from days 1 to 3. Nonsteroidal anti-inflammatory drug (NSAID) medication was helpful to relieve the fever, but the fever reappeared several times within the first 4 days.</s><s>We considered the fever as the most significant event in response to cell infusion.</s><s>Most patients with a grade 3/4 lymphocyte count decrease were expected because of lymphodepletion.</s><s>After lymphodepletion, the lymphocyte levels dropped to approximately 0.1 Â 10 9 /mL on day 0, and most patients recovered to approximately 0.5 Â 10 9 /mL within the first week (Figure <ref type="figure" target="#fig_1">S2A</ref>).</s><s>The neutrophil count was also influenced by lymphodepletion in some patients.</s><s>We also assumed that the decrease of platelet (PLT) in P7 and both the alopecia and the gastritis in P10 were related to lymphodepletion.</s><s>P8 had a duodenum perforation on day 20 after cell infusion.</s><s>CD3 + cells were not found in the specimen of the perforating site (data not shown).</s><s>This adverse event was not related to CAR-T therapy, and we suspected it to be due to dyspepsia.</s><s>The hepatic pain of P1 and the abdominal pain of P6 were due to tumor lesions.</s><s>Abnormal hepatic functions were observed only in patients with a high tumor burden (diameter &gt;8 cm) of liver metastasis (P1, P5, and P9).</s><s>Their gamma-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP) were in gradual deterioration (Figure <ref type="figure" target="#fig_1">S2B</ref>).</s><s>Sudden hepatic function degradation was not detected in any patient.</s><s>Although the gastrointestinal tract tissue showed CEA expression and was most likely to have the side effect of colitis, there was no colitis even at the high-dose infusion.</s><s>We also monitored renal function (blood urea nitrogen [BUN], serum creatine, electrolyte, and uric acid levels) and coagulation function (activated partial thromboplastin time [APTT], thrombin time [TT], and international normalized ratio [INR]).</s><s>Abnormalities were not observed.</s><s>Moreover, abnormalities of the cardiac system (hypertension/hypotension and arrhythmia) and respiratory system (cough and respiratory distress) were not seen in any patient.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>C-Reactive Protein and Cytokines</head><p><s>C-reactive protein (CRP) and IL-6 have been demonstrated to be sensitive markers for the diagnosis of cytokine release syndrome (CRS), and these two factors had a favorable correlation. <ref type="bibr" target="#b11">12,</ref><ref type="bibr" target="#b12">13</ref></s><s>Thus, CRP and IL-6 were immediately measured in the laboratory department of Southwest Hospital each time that the trial procedure was recommended.</s><s>Most patients in low DL and high DL showed a certain degree of single-peak CRP levels within the first week (Figures <ref type="figure" target="#fig_1">2A and 2B</ref>).</s><s>IL-6 levels behaved similarly (Figure <ref type="figure" target="#fig_1">S2C</ref>).</s><s>The CRP and IL-6 levels of P2, P6, and P8 were constantly negative.</s><s>Most factors among CRP and the 15 cytokines had the same parabolic trend of a single peak level, especially in high DL infusion (Figure <ref type="figure" target="#fig_1">2C</ref>; Figure <ref type="figure" target="#fig_1">S2D</ref>).</s><s>We performed Spearman's correlation analysis to determine the correlations between CRP and each of the 15 cytokines (n = 93; Table <ref type="table" target="#tab_2">S2</ref>).</s><s>Among the CRP and cytokine levels we measured, interferon (IFN)-g was correlated with all the factors except IP-10 and MIG (Figure <ref type="figure" target="#fig_1">2D</ref>).</s><s>CRP was correlated with another eight factors.</s><s>Fractalkine, IL-1RA, IL-2, and MIP-1a were correlated with another 11 factors.</s><s>However, levels of IL-1RA and IL-2 were mostly undetectable.</s><s>IP-10 and MIG were only correlated with two and four other factors, respectively.</s><s>Because of the fever of Ps 7 and 10, we suspected that IFN-g is an even more sensitive indicator for cytokine release syndrome than CRP (Figures <ref type="figure" target="#fig_1">2E and 2F</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Clinical Evaluation of CAR-T Therapy</head><p><s>We conducted the clinical evaluation of CEA CAR-T therapy through CEA level monitoring and lesion analysis.</s><s>The CEA levels were analyzed and illustrated (Figure <ref type="figure" target="#fig_2">3A</ref>).</s><s>The serum CEA level of P6 was negative, but CEA expression was confirmed by immunohistochemistry (IHC) (see Table <ref type="table" target="#tab_0">1</ref>).</s><s>Most patients had an apparent decrease in the CEA levels as response to CAR-T therapy, especially in long-term observation.</s><s>Serum CEA dropped to a satisfactory level, and the decline convinced us of the efficacy of CEA CAR-T therapy.</s><s>The short-term outcomes were determined by comparing the diameters of imagological lesions between enrollment and 4 weeks after cell infusion according to irRECIST (Immune-related Response Evaluation Criteria In Solid Tumors) (see Table <ref type="table" target="#tab_0">1</ref>).</s><s>Long-term observation of tumor lesions was also conducted according to standard procedures.</s><s>Seven out of 10 patients who experienced progressive disease (PD) in previous treatments had stable disease with slight variation in the tumor diameters after CAR-T therapy.</s><s>Ps 3 and 5 had remained with stable disease for more than 30 weeks.</s><s>The positron emission tomography (PET)/computed tomography (CT) of P9-2 showed apparent attenuation of tumor activity (Figure <ref type="figure" target="#fig_2">3B</ref>), with standard uptake value (SUV) max attenuation from 7.38 (enrollment) to 5.80 (fourth week).</s><s>Moreover, we observed the shrinkage of one liver lesion in P10 receiving DL4 by MRI (Figure <ref type="figure" target="#fig_2">3C</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Persistence of CAR-T Cells in Peripheral Blood and Tumor Tissues</head><p><s>Existence and persistence of CAR-T cells were measured in peripheral blood by FCM using Protein L that is a novel reagent for CAR-T detection <ref type="bibr" target="#b13">14</ref> or recombinant CEA protein with His tag, and by qPCR for detection of DNA copy numbers.</s><s>CAR-T cells were undetectable in peripheral blood by FCM using either Protein L or CEA.</s><s>qPCR data showed that most of the patients had increasing DNA copies of CAR-T cells in the first few days in accordance with CAR-T infusion.</s><s>For patients receiving low CAR-T doses (DL1 and DL2), changes of DNA copies were not significant and high number of DNA copies was not observed.</s><s>However, patients receiving high doses (DL3-DL5) showed apparent DNA changes as signs to CAR-T cell infusion (Figure <ref type="figure" target="#fig_3">4</ref>).</s><s>Most of the patients quickly manifested a peak level of DNA copies after CAR-T infusion, and some patients even had a second peak level in a few weeks after CAR-T infusion.</s><s>Moreover, for the three patients receiving a second CAR-T therapy 6-7 weeks after the first CAR-T therapy, DNA copies sustained high levels for a couple of days in patients receiving DL5 (P7-2 and P9-2; Figures <ref type="figure" target="#fig_3">4B, 4D, and 4E</ref>).</s><s>Nonetheless, DNA copies of all patients declined to undetectable levels 4-6 weeks post CAR-T infusion.</s><s>In addition, tumor biopsies from three patients (P5: right adrenal gland; P6: greater omentum; P7-2: lung) on the fourth week after cell infusion were obtained.</s><s>These specimens were formalin fixed and paraffin embedded (FFPE).</s><s>We found CD3 + T cells in these tumor specimens by immunohistochemistry (IHC) (Figure <ref type="figure" target="#fig_4">5A</ref>).</s><s>DNA copy number in tumor tissues of Ps 6 and 7-2 was 1,029.22 and 983.29/mg genomic DNA, respectively (Figure <ref type="figure" target="#fig_4">5B</ref>).</s><s>The specimen material of P5 was not sufficient for qPCR detection.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Phenotypes of Peripheral Blood Mononuclear Cells in the Peripheral Blood</head><p><s>To monitor the immune environment and peripheral blood mononuclear cells (PBMCs) phenotypes, we conducted weekly follow-up of the FCM detection of the PBMCs (Figures <ref type="figure" target="#fig_5">6A and 6B</ref>; Figure <ref type="figure" target="#fig_2">S3</ref>).</s><s>We used the PBMC data at the time of enrollment as the baseline.</s><s>Immune-suppressive factors, including the myeloid-derivced suppressor cells (MDSC) (CD14 + CD45 + HLA-DR À ) and regulatory T cell (Treg) (CD4 + CD25 + CD127 À ) proportions in PBMCs and checkpoint inhibitors (PD-1) in T cells, tended to increase within the first 2 weeks (Figure <ref type="figure" target="#fig_5">6A</ref>).</s><s>Within the first 2 weeks, several patients seemed to have an apparent rise in the MDSC and PD-1 levels among PBMCs and T cells, respectively (Figure <ref type="figure" target="#fig_5">6B</ref>).</s><s>The proportions of TIM-3 and LAG-3 on T cells of most patients were undetectable (data not shown).</s><s>The lymphocyte subtypes and CD4/8 ratio were determined (Figure <ref type="figure" target="#fig_2">S3A</ref>).</s><s>There was no difference in the CD4/8 ratio between CAR + and CD3 + (p &lt; 0.01).</s><s>Moreover, the Tn proportion in T cells tended to drop constantly, whereas Tcm and Tem increased to a certain extent (Figure <ref type="figure" target="#fig_2">S3B</ref>).</s><s>High proportion cells of CD45RA + CD45RO + was detected.</s><s><ref type="bibr" target="#b16">[17]</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Carbohydrate Antigen</head><p><s>Carbohydrate antigens are widely expressed in CRC and are biomarkers for CRC, but they lack sensitivity and specificity.</s><s>Carbohydrate antigens, including CA125, CA242, CA19-9, CA724, and CA50, were measured accompanying CEA.</s><s>Only CA242 (n = 61; correlation coefficient, 0.539) correlated with CEA among the five carbohydrate antigens (Figure <ref type="figure" target="#fig_3">S4A</ref>).</s><s>Even so, none of the carbohydrate antigens exhibited apparent variation or deterioration, and they were well controlled (Figure <ref type="figure" target="#fig_3">S4B</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p><s>In this clinical trial, we applied CEA CAR-T clinical trials in 10 refractory CRC patients with liver and lung metastasis.</s><s>We have chosen humanized scFv BW431/26 to target CEA because it has been proved not to be blocked by serum CEA. <ref type="bibr" target="#b17">18,</ref><ref type="bibr" target="#b18">19</ref></s><s>Our data showed that CD28 intracellular signaling played a better role in cytokine excretion and cytotoxicities to CEA + CRC cells than CD137 signaling.</s><s>Moreover, we also found that third generation of CAR with CD28 and CD137 signaling did not show better cytokine excretion and cytotoxicities than second generation with CD28 signaling (data not shown).</s><s>Based on these preclinical studies, we used this newly constructed CEA CAR-T for further clinical trial.</s><s>Our data showed that 7 of 10 patients who experienced PD in previous treatments had stable disease after CAR-T therapy.</s><s>Two patients remained with stable disease for more than 30 weeks, and two patients experienced tumor shrinkage by PET/CT and MRI analysis, respectively.</s><s>Decline of serum CEA level was apparent in most patients even in long-term observation.</s><s>These data indicated promising efficacy of CEA CAR-T therapy on refractory CRC patients with metastasis.</s><s>Recent study has shown that a patient with recurrent multifocal glioblastoma receiving IL-13Ra2 CAR-T cells by multiple infusions of CAR-T cells over 220 days through two intracranial delivery routes exhibited regression of all intracranial and spinal tumors. <ref type="bibr" target="#b5">6</ref></s><s>This extremely exciting result will push forward the field of CAR-T therapy in solid tumors.</s></p><p><s>Previous studies have demonstrated that high complete remission rate of CAR-T therapy on hematological malignancies was based on expansion and long-term persistence of CAR-T cells in peripheral blood, and loss of CAR-T cells in peripheral blood resulted in relapse of diseases. <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b11">12</ref></s><s>Thus, expansion and persistence of CAR-T cells may predict outcome of cancer patients after CAR-T therapy.</s><s>In our study, we found that CAR-T cells could be detected and expanded in both peripheral blood and tumor tissues of those patients receiving high doses of CAR-T therapy.</s><s>However, it persisted for only a short time from a few days to weeks.</s><s>Interestingly, the second infusion of CAR-T could achieve similar levels of CAR-T expansion and persistence as the first administration.</s><s>However, CAR-T cells in peripheral blood were detected only by a sensitive method using qPCR, but not by FCM using Protein L, which is a novel reagent for CAR-T detection <ref type="bibr" target="#b13">14</ref> and CEA-His protein.</s><s>Previous studies showed that detection of CAR-T cell by copy numbers could be as high as 100,000 copies/mg genomic DNA (gDNA) in the early time after CART cell infusion in some clinical trials. <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b19">20</ref></s><s>Our CAR-T copy numbers are less than 1,000, indicating the actual CAR-T cells in the blood are less than 0.1%, and this is out of the detection sensitivity of FCM based on protein L or CEA-His protein.</s><s>Low level of CAR-T in the cerebrospinal fluid was also found in the successful treatment of multifocal glioblastoma by IL-13Ra2 CAR-T cells, <ref type="bibr" target="#b5">6</ref> as well as in other studies by using CAIX CAR-T and HER2 CAR-T therapies. <ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b8">9</ref></s><s>other important issue of CAR-T therapy is adverse events of cytokine release syndrome (CRS) and on-target/off-tumor effects.</s><s>The serious CRS was frequently observed in hematological malignancies treated by CAR-T cells, particularly in patients receiving cyclophosphamide (CTX)/fludarabine (FLU) lymphodepletion before CAR-T infusion. <ref type="bibr" target="#b20">21</ref></s><s>However, the serious CRS is not common in solid tumor treated by CAR-T cells. <ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b6">7</ref></s><s>Our data showed that only minor CRS was observed in patients receiving high doses of CAR-T cells.</s><s>It is coincident to other reports. <ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b6">7</ref></s><s>However, on-target/off-tumor effects are common and remain a concern when designing a CAR trial.</s><s>Lamers et al. <ref type="bibr" target="#b3">4</ref> showed that CAIX-targeting CAR-T cells exerted antigen-specific effects and induced liver toxicity at the lowest dose of 0.2 Â 10 9 T cells.</s><s>The HER2 CAR-T cells were localized to the lung immediately following infusion and were triggered to release cytokine by the recognition of low levels of HER2 on lung epithelial cells, resulting in patient death after the high dose of 10 10 was applied. <ref type="bibr" target="#b21">22</ref></s><s>A severe transient inflammatory colitis was induced in all three patients after treatment with autologous T lymphocytes genetically engineered to express a murine T cell receptor (TCR) against CEA (TCR-T). <ref type="bibr" target="#b7">8</ref></s><s>However, our study and a study from Katz et al. <ref type="bibr" target="#b6">7</ref> did not observe inflammatory colitis even in high doses of 5 Â 10 9 and 10 10 CEA CAR-T cells that we have applied, respectively.</s><s>This may be because CEA CAR-T cells did not reach to the lumen where CEA is expressed on the apical surface of normal epithelial cells in gastrointestinal tracts. <ref type="bibr" target="#b9">10</ref></s><s>In contrast, severe transient colitis caused by the destruction of normal epithelial cells by CEA TCR-T may be induced by the nonpolarized expression of MHC class I molecules bound to CEA peptides on CEA-expressing healthy epithelial cells. <ref type="bibr" target="#b7">8,</ref><ref type="bibr" target="#b22">23</ref></s><s>mphodepletion by CTX/FLU has been shown to attenuate immune suppression factors and allow CAR-T cell expansion. <ref type="bibr" target="#b23">24</ref></s><s>Although it is not widely accepted in solid malignancies, lymphodepletion has been proved to be effective and necessary for immunotherapy against solid tumors. <ref type="bibr" target="#b23">24,</ref><ref type="bibr" target="#b24">25</ref></s><s>We demonstrated that high-dose lymphodepletion (cyclophosphamide [CTX], 900 mg/kg/day) was tolerated in most patients and lymphodepletion-related infection was controllable.</s><s>Previous studies have demonstrated that naive T cells are thought to be the most effective and may enhance cell proliferation and persistence. <ref type="bibr" target="#b10">11</ref></s><s>ptimal methodology to improve this population in future trials may yield better results.</s><s>Defined CD8 + and CD4 + subsets of CAR-T products were meaningful for superior antitumor activity. <ref type="bibr" target="#b25">26,</ref><ref type="bibr" target="#b26">27</ref></s><s>Moreover, enhancing T cell proliferation and persistence in the tumor site increases the efficacy.</s><s>Increasing telomerase activity has been proved to increase the persistence and long-term antitumor efficacy of CAR-T cells. <ref type="bibr" target="#b27">28</ref></s><s>In addition, systemic cytokines such as IL-2 may increase CAR-T number and function.</s><s>Co-stimulatory signals of the CAR-T structure are also significant for CAR-T function.</s><s>0]<ref type="bibr" target="#b30">[31]</ref> The superposition of signals may not be suitable in this study.</s><s>The further investigations regarding the optimal combination of signals are needed.</s><s>T cell accumulation was less in parenchyma compared with mesenchyma (Figure <ref type="figure" target="#fig_5">6C</ref>).</s><s>Thus, enhanced chemotaxis of CAR-T was also significant, and combination with chemokine receptors was elucidated to strengthen CAR-T function. <ref type="bibr" target="#b31">32</ref></s><s>ken together, in this clinical trial of 10 relapsed and refractory CRC patients with metastasis, several patients obtained stable disease after treatment with CEA CAR-T cells, without significant CAR-related toxicity.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MATERIALS AND METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study Description</head><p><s>This study was approved by the Ethics Committee of the Southwest Hospital of Third Military Medical University (Chongqing, China) and Second Affiliated Hospital of Chongqing Medical University (Chongqing, China).</s><s>This study was done according to the principles of the Declaration of Helsinki.</s><s>All participants were informed of the trial procedure, possible risks, and adverse effects of the therapy.</s><s>They voluntarily provided written informed consent for enrollment.</s><s>The registration number on Clinicaltrials.gov is NCT02349724.</s><s>No commercial sponsor was involved in the study.</s><s>Eligible patients had measurable lesions and failed more than one line of systemic therapy.</s><s>All patients had completed their antitumor therapies (e.g., chemotherapy) more than 2 weeks before enrollment.</s><s>The interval of radio-logical examinations between enrollment and lymphodepletion was less than 1 month.</s><s>CEA intensity was confirmed by immunohistochemistry (IHC).</s><s>CEA staining was graded into three levels (+, ++, and +++), and the proportion of tumor cells at each level was judged by a blinded pathologist (see Table <ref type="table" target="#tab_0">1</ref>).</s><s>Normal left ventricular ejection fraction (LVEF) had been confirmed for every patient.</s><s>Moreover, patients were excluded if they had a hematological abnormity with a hemoglobin level less than 9 g/dL, a white blood cell (WBC) count less than 2,000/mL, an absolute neutrophil count less than 1,000/mL, or a platelet count less than 50,000/mL.</s><s>Regarding hepatic and renal function, the patients were required to have a serum bilirubin level less than 3Â the upper limit of normal, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) less than 3Â (without liver metastasis)/5Â (with liver metastasis) the upper limit of normal, and BUN or creatine levels less than 3Â the upper limit of normal.</s></p><p><s>There was a standard procedure for the management of each patient (Figure <ref type="figure" target="#fig_0">1A</ref>).</s><s>Basic radiological examinations and blood tests were administrated to judge whether the patient fit the enrollment criteria.</s><s>CAR-T preparation lasted 14-16 days, and lymphodepletion lasted 5 consecutive days.</s><s>The first four patients received CTX 300 mg/kg/day for 3 days, whereas the dose for the other patients was 900 mg/kg/day (see Table <ref type="table" target="#tab_0">1</ref>).</s><s>All of the patients had fludarabine (FLU) 25 mg/kg/day for the last 2 days.</s><s>The day after completing lymphodepletion, blood tests (routine blood analysis and measurements of C-reactive protein, CEA, and hepatic and renal function) were applied for the evaluation of the patient status for CAR-T infusion.</s><s>An escalating dose was administrated based on safety considerations, and five DLs were set: 1 Â 10 5 , 5 Â 10 5 , 1 Â 10 6 , 1 Â 10 7 , and 1 Â 10 8 /CAR + /kg cells.</s><s>Each DL had three patients except for DL4 (1 Â 10 7 ) with two patients because a newly enrolled patient withdrew before lymphodepletion.</s><s>Systemic IL-2 or other cytokine delivery was not administrated.</s><s>To ensure safety, each patient received 10%, 30%, and 60% of the total cells on the first 3 days.</s><s>Weekly follow-up lasted for 4 weeks, and radiological assessment was executed on the fourth week.</s><s>The long-term follow-up schedule was not shown.</s><s>All responses were evaluated according to the lesion diameter and immune-related response criteria (irRECIST). <ref type="bibr" target="#b32">33,</ref><ref type="bibr" target="#b33">34</ref></s><s>Adverse events were graded according to</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patient Characteristics</head><p><s>In total, 10 CRC patients with metastasis fit the criteria and were recruited (Table <ref type="table" target="#tab_2">2</ref>).</s><s>Most patients had liver metastasis (8/10), and half of the patients had lung metastasis (5/10).</s><s>Eight of 10 patients had primary lesion resection (enterectomy).</s><s>No patient has a Karnofsky score (KPS) below 80, and all patients were adenocarcinoma according to the pathology results.</s><s>Eight patients were enrolled at Southwest Hospital, whereas the other two were enrolled at The Second Affiliated Hospital, Chongqing Medical University.</s><s>All of the blood samples were tested at Southwest Hospital.</s><s>The median number of lines of chemotherapy of patients was 2.5 (range, 1.25-3 lines).</s><s>The median age was 58 years (range, 48.8-67 years).</s><s>All of the radiological examinations (CT, MRI, or PET) were administrated within 4 weeks before lymphodepletion.</s><s>Among the 10 patients, 4 (P1, P7, P9, and P10) received two different doses of infusions (Table <ref type="table" target="#tab_0">1</ref>).</s><s>The interval between the two infusions was more than 6 weeks.</s><s>The other six patients received only one infusion.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Generation and Quality Control of CEA CAR-T Cells</head><p><s>Lentivirus was produced and purified from the supernatant of 293T cells with transfection of the pCDH lentiviral plasmid, envelope plasmid PMD2.G, packaging plasmid (pMDLg/pRRE), and plasmidproducing Rev regulatory protein (pRSV-Rev), as we described previously. <ref type="bibr" target="#b34">35</ref></s><s>The pCDH lentiviral plasmid consisted of BW431/26 scFv-IgG4 hinge-CD28 transmembrane domain-CD28-CD3z.</s><s>Peripheral blood was collected from patients, and peripheral blood mononuclear cells (PBMCs) were isolated on day 1.</s><s>PBMCs were activated by immobilized CD3 (MACS, 170-076-116) and CD28 (MACS, 170-076-117) antibodies.</s><s>On day 2, T cells were infected with lentiviral vector in six-well plates (1 Â 10 6 cells/well, 5 MOI) with polybrene.</s><s>After viral transduction, T cells were expanded by IL-2 (100 U/ml) for approximately 12-14 days to obtain enough cell dose.</s><s>Quality control of cell products was performed by FCM.</s><s>For the cell products, the CAR + %, proportion of T cells (CD3 + ), NK cells (CD16 + CD56 + ), NKT cells (CD3 + CD16 + CD56 + ), CD4/8 ratio, T memory cells, and checkpoint inhibitors (TIM-3, PD-1, LAG-3) on the T cell surface were measured (Figures <ref type="figure" target="#fig_0">1B-1E</ref>) on the day before CAR-T infusion.</s></p><p><s>To ensure transfection, we also applied CAR + % detection 4-5 days after viral transfection.</s><s>(536422; BD Biosciences), PD-1 (560908; BD Biosciences), and LAG-3 (565616; BD Biosciences) were also detected in CD4 + and CD8 + cells.</s><s>Lymphocyte subtypes were measured using the MultiTEST IMK Kit (340503; BD Biosciences).</s><s>Isotype antibodies and untransduced T cells (UTD) were used as controls.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Quantitative DNA Copies</head><p><s>Blood samples were obtained according to the trial procedure (Figure <ref type="figure" target="#fig_0">1A</ref>).</s><s>Genomic DNA was extracted from the blood samples using a QIAamp DNA Blood Mini Kit (51106; QIAGEN) and following the protocol.</s><s>We applied TaqMan probes for qPCR in an ABI ViiA 7.</s></p><p><s>TaqMan primers were 5 0 -GAGGACATCGCCACCTACTACTG-3 0 (forward) and 5 0 -GTCCCTTGGCCGAACGT-3 0 (reverse).</s><s>Probe was 5 0 -7VIC-ATCAGTGGAGTAGTTATC-3 0 .</s><s>The TaqMan method was performed in accordance with the published protocol. <ref type="bibr" target="#b35">36</ref></s><s>CDKN1A was used as the control and produced a correction factor (CF) for correction of DNA copy number.</s><s>Healthy donor DNA sample was detected as negative control and definition of pre-infusion acceptance ranges of qPCR method.</s><s>The lower limit of quantification (LLOQ) was determined at 50 copies/mg genomic DNA.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cytokines</head><p><s>Plasma samples were stored at À80 C and were analyzed in batches using a 15-plex human cytokine magnetic bead panel (SPR372;</s></p><p><s>Milliplex) with the MAGPIX instrument (Luminex).</s><s>The levels of factors including IL-2, IL-6, IL-10, Fit-3L, Fractalkine, GM-CSF, IFN-g, tumor necrosis factor alpha (TNF-a), IL-2Ra, IL-1RA, MIG (CXCL9), IP-10, MCP-1, MIP-1a, and MIP-1b were measured.</s><s>Samples were undiluted, and each was assayed in duplicate.</s><s>Data analysis was conducted according to the related protocol and algorithm.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical Analysis</head><p><s>Descriptive statistics (median and ranges) were used to aggregate the data.</s><s>Comparison of the CD4/8 ratio in CAR + and CD3 + cells was performed using a paired t test.</s><s>The levels of CEA, carbohydrate antigens, and cytokines were not normally distributed.</s><s>The correlation between CEA and other carbohydrate antigens was determined by Spearman's correlation.</s><s>Spearman's correlation was also applied to analyze the correlation between C-reactive protein (CRP) and cytokines.</s><s>The correlation coefficient was also calculated.</s><s>p &lt; 0.05 was considered to be statistically significant.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>SUPPLEMENTAL INFORMATION</head><p><s>Supplemental Information includes four figures and two tables and can be found with this article online at http://dx.doi.org/10.1016/j.</s><s>ymthe.2017.03.010.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc><div><p><s>Figure 1.</s><s>Procedure of Clinical Trial and Characteristics of CAR-T Cells (A) Trial schedule.</s><s>Basic imagological examinations and blood tests were needed for enrollment screening.Between the completion of lymphodepletion and initiation of CAR-T infusion, blood tests were administered on day 0 to reconfirm whether the patient could tolerate cell infusion.</s><s>CAR-T infusion was executed on days 1, 2, and 3, and 10%, 30%, and 60% of the total cell dose were administrated, respectively.</s><s>(B-E) Characteristics of CAR-T cells were analyzed by FCM results for quality control of the CAR-T cell products.</s><s>For each product, the ratios of T cells, NK cells, NKT cells, and CAR-T cells were measured before infusion.</s><s>There was no difference in CD4/8 between CAR + cells and CD3 + cells.</s><s>Tm cells and checkpoint inhibitors were also detected.</s><s>E, enrollment.</s></p></div></figDesc><graphic coords="2,48.87,110.67,321.55,309.60" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2 .</head><label>2</label><figDesc><div><p><s>Figure 2. CRP and Cytokines Detection for Immune Monitoring CRP levels were divided into two groups according to the DLs.</s><s>(A and B) The DL1/2/3 (A) and DL4/5 (B) levels are shown.</s><s>(C) All cytokines and CRP of Ps 7 (left) and 10 (right) are shown.</s><s>Most factors exhibited a similar trend as an immune response.</s><s>(D) Spearman's correlation of IFN-g and CRP with other cytokines.</s><s>n = 93.</s><s>Each correlation coefficient and significance is shown.</s><s>IFN-g correlated with all factors except IP-10 and MIG.</s><s>(E and F) The IFN-g and CRP levels of Ps 7 (E) and 10 (F) receiving DL 5 were compared.</s></p></div></figDesc><graphic coords="3,48.87,110.67,321.55,402.46" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 3 .</head><label>3</label><figDesc><div><p><s>Figure 3. Clinical Evaluation of CAR-T Therapy (A) Most patients showed the decreased CEA levels in response to CAR-T therapy.</s><s>(B) PET/CT assessment of P9-2 receiving DL5 before (left) and 4 weeks after (right) CAR-T infusion.</s><s>(C) MRI assessment of P10 receiving DL4 before (left) and 4 weeks after (right) CAR-T infusion.</s></p></div></figDesc><graphic coords="4,57.03,110.61,488.86,292.88" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 4 .</head><label>4</label><figDesc><div><p><s>Figure 4. Detection of DNA Copies of CAR-T Cells in Peripheral Blood Detection of DNA copies of CAR-T cells in peripheral blood.</s><s>The panels (A)-(E) are represented as an individual patient.</s><s>DNA copies were detectable after a high dose of CAR-T infusion and proliferation of CAR-T cells were also observed in some patients a few weeks after CAR-T infusion.</s></p></div></figDesc><graphic coords="6,91.62,110.61,419.73,236.30" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Figure 5 .</head><label>5</label><figDesc><div><p><s>Figure 5. CAR-T Trafficking in Tumor Tissues (A) CD3 + cells were detected in metastatic tumor tissues obtained at the fourth week after CAR-T infusion by IHC staining.</s><s>Ps 5 (left), 6 (middle), and 7-2 (right) receiving DL2, DL3, and DL5 are shown, respectively.</s><s>(B) DNA copies of CAR-T cells in tumor tissue of Ps 6 and 7-2 are presented.</s></p></div></figDesc><graphic coords="7,92.81,110.61,417.31,99.50" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Figure 6 .</head><label>6</label><figDesc><div><p><s>Figure 6.</s><s>Immune-Suppressive Factor Levels after CAR-T Infusion and CAR-T Distribution in Tumor Site (A and B) Follow-up detection of MDSCs, Tregs, the PD-1 proportion of PBMCs, and T cells in peripheral blood.</s><s>n = 10.</s><s>The CD8 À gate was regarded as CD4 + .</s><s>(C) CD3 staining of puncture tissue of P7-2.</s><s>T cells showed much greater accumulation in the mesenchyma than the parenchyma.</s></p></div></figDesc><graphic coords="8,57.03,110.61,488.86,247.07" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Therapeutic-Related Information and Outcome</s></p></div></figDesc><table><row><cell>ID</cell><cell>CEA Intensity Score (%)</cell><cell>CAR-T Dose</cell><cell>Total Cell Counts</cell><cell>CAR + %</cell><cell>Lymphodepletion</cell><cell>Outcome a</cell></row><row><cell>1</cell><cell>75 (+++) + 25 (++)</cell><cell>DL1</cell><cell>2.5 Â 10 7</cell><cell>20</cell><cell></cell><cell>PD</cell></row><row><cell>1-2 b</cell><cell>75 (+++) + 25 (++)</cell><cell>DL2</cell><cell>1.25 Â 10 8</cell><cell>20</cell><cell></cell><cell>PD</cell></row><row><cell>2</cell><cell>100 (+++)</cell><cell>DL1</cell><cell>2.5 Â 10 7</cell><cell>37</cell><cell>CTX 300 mg/m 2 Â 3 days FLU 25 mg/m 2 Â 2 days</cell><cell>stable disease</cell></row><row><cell>3</cell><cell>100 (+++)</cell><cell>DL1</cell><cell>4 Â 10 7</cell><cell>4</cell><cell></cell><cell>stable disease c</cell></row><row><cell>4</cell><cell>70 (++)</cell><cell>DL2</cell><cell>2.5 Â 10 8</cell><cell>15</cell><cell></cell><cell>PD</cell></row><row><cell>5</cell><cell>100 (+++)</cell><cell>DL2</cell><cell>8.6 Â 10 7</cell><cell>34</cell><cell></cell><cell>stable disease d</cell></row><row><cell>6</cell><cell>100 (+++)</cell><cell>DL3</cell><cell>2.5 Â 10 8</cell><cell>22</cell><cell></cell><cell>stable disease</cell></row><row><cell>7</cell><cell>70 (+++)</cell><cell>DL3</cell><cell>1.6 Â 10 8</cell><cell>59</cell><cell></cell><cell>stable disease</cell></row><row><cell>8</cell><cell>100 (+++)</cell><cell>DL3</cell><cell>3.9 Â 10 9</cell><cell>8</cell><cell></cell><cell>N E</cell></row><row><cell>9</cell><cell>100 (+++)</cell><cell>DL4</cell><cell>2.1 Â 10 9</cell><cell>39</cell><cell>CTX 900 mg/m 2 Â 3 days FLU 25 mg/m 2 Â 2 days</cell><cell>stable disease</cell></row><row><cell>10</cell><cell>100 (+++)</cell><cell>DL4</cell><cell>9.8 Â 10 8</cell><cell>56</cell><cell></cell><cell>stable disease</cell></row><row><cell>7-2 b</cell><cell>70 (+++)</cell><cell>DL5</cell><cell>1.5 Â 10 10</cell><cell>43</cell><cell></cell><cell>stable disease d</cell></row><row><cell>9-2 b</cell><cell>100 (+++)</cell><cell>DL5</cell><cell>1.31 Â 10 10</cell><cell>14</cell><cell></cell><cell>stable disease d</cell></row><row><cell>10-2 b</cell><cell>100 (+++)</cell><cell>DL5</cell><cell>8.2 Â 10 9</cell><cell>66</cell><cell></cell><cell>stable disease</cell></row><row><cell cols="2">DL, dose level; NE, not evaluable.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>a Therapeutic evaluation at the fourth week after CAR-T infusion.</s><s>b P1-2, P7-2, P9-2, and P10-2 represent second time of infusion of Ps 1, 7, 9, and 10, respectively.</s><s>DL1 to DL5 represent escalating DLs, which represent 1 Â 10 5 , 5 Â 10 5 , 1 Â 10 6 , 1 Â 10 7 , and 1 Â 10 8 /CAR + /kg cells, respectively.</s><s>For lymphodepletion, the first four patients received low-dose cyclophosphamide (CTX), whereas the others received high-dose CTX.</s><s>c Patient 3 exhibited stable disease for more than 34 weeks with other chemotherapy administered at 4 weeks after CAR-T infusion.</s><s>d Patients 5, 7-2, and 9-2 exhibited stable disease for more than 33, 13, and 14 weeks, respectively.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 2 .</head><label>2</label><figDesc><div><p><s>Patient Characteristics Lesionectomy was canceled for P6 because of extensive abdominal metastasis found during surgery.</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Living</cell></row><row><cell></cell><cell>Age</cell><cell>Primary</cell><cell></cell><cell></cell><cell></cell><cell>Lesion</cell><cell>Largest</cell><cell></cell><cell></cell><cell>Latest</cell><cell>Interval</cell></row><row><cell>ID Sex</cell><cell>(years)</cell><cell>Lesion</cell><cell cols="3">Resection a Differentiation Metastasis</cell><cell>Number b</cell><cell cols="2">Size (cm) c Prior Chemotherapy</cell><cell>Other Agents</cell><cell>Evaluation d</cell><cell>(months) e</cell></row><row><cell cols="2">1 M 61</cell><cell>sigmoid</cell><cell>Y</cell><cell>median</cell><cell>liver</cell><cell>&gt;10</cell><cell>13.4</cell><cell>XELOX</cell><cell>N</cell><cell>PD</cell><cell>14</cell></row><row><cell cols="2">2 M 37</cell><cell>transverse colon</cell><cell>Y</cell><cell>median</cell><cell>liver, LN</cell><cell>1</cell><cell>4.5</cell><cell>FOLFOX</cell><cell>N</cell><cell>PD</cell><cell>19</cell></row><row><cell cols="2">3 M 70</cell><cell>rectum</cell><cell>N</cell><cell>median</cell><cell>liver, lung, LN</cell><cell>&gt;10</cell><cell>4.8</cell><cell>XELOX, FOLFOX, XELIRI, bevacizumab</cell><cell>CIK</cell><cell>stable disease</cell><cell>21</cell></row><row><cell cols="2">4 M 69</cell><cell>rectum</cell><cell>Y</cell><cell>low</cell><cell>liver, lung, LN</cell><cell>&gt;10</cell><cell>8.2</cell><cell>FOLFOX6, FOLFORI</cell><cell>radiotherapy</cell><cell>PD</cell><cell>21</cell></row><row><cell cols="2">5 M 68</cell><cell>sigmoid</cell><cell>Y</cell><cell>median</cell><cell>liver, RAG, LN</cell><cell>2</cell><cell>9.2</cell><cell>FOLFOX, FOLFORI, Xeloda</cell><cell>radiotherapy</cell><cell>PD</cell><cell>22</cell></row><row><cell>6 F</cell><cell>51</cell><cell cols="2">ileocecum f N</cell><cell>median</cell><cell>enterocoelia</cell><cell cols="2">extensive 6.8</cell><cell cols="2">FOLFORI, bevacizumab N</cell><cell>PD</cell><cell>6</cell></row><row><cell cols="2">7 M 64</cell><cell>rectum</cell><cell>Y</cell><cell>median</cell><cell>liver, lung</cell><cell>&gt;10</cell><cell>2.4</cell><cell>FOLFOX, FOLFORI, XELOX</cell><cell>N</cell><cell>P D</cell><cell>3 7</cell></row><row><cell>8 F</cell><cell>37</cell><cell>ascending colon</cell><cell>Y</cell><cell>median</cell><cell>vertebra, LN</cell><cell>1</cell><cell>NE</cell><cell>FOLFOX, MFOLFOX, XELOX, IRIS, bevacizumab, Xeloda</cell><cell>radiotherapy</cell><cell>stable disease</cell><cell>16</cell></row><row><cell cols="2">9 M 48</cell><cell>ascending colon</cell><cell>Y</cell><cell>median</cell><cell>liver, lung, LN</cell><cell>&gt;10</cell><cell>10.8</cell><cell>FOLFOX, XELOX, FOLFIRI, SOX</cell><cell>CIK, RF</cell><cell>PD</cell><cell>77</cell></row><row><cell>10 F</cell><cell>55</cell><cell>rectum</cell><cell>Y</cell><cell>median</cell><cell>liver, lung, anastomosis, LN</cell><cell>9</cell><cell>1.9</cell><cell>CAPEOX, Xeloda, bevacizumab</cell><cell cols="2">radiotherapy, RF PD</cell><cell>32</cell></row></table><note><p><s>CIK, cytokine-induced killers; F, female; LN, lymph node; M, male; N, no; NE, lesions on the vertebrae and lymph nodes were not evaluable; RAG, right adrenal gland; RF, radiofrequency ablation on liver lesions; Y, yes.a</s><s>Resection represents primary lesion resection.</s><s>b Lesion numbers do not include primary lesion and lymph node lesions.</s><s>c Largest size is long diameter of the largest metastatic lesion.</s><s>d Living interval is months from the first diagnosis to CAR-T infusion.</s><s>e Latest evaluation before enrollment.</s><s>f</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Molecular Therapy Vol. 25 No 5 May 2017</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACKNOWLEDGMENTS</head><p><s>Xuejiao Chen, Honghao Chen, Zhouqin Yang, and Yi Huang at the Biotherapy Center of Southwest Hospital produced the plasmid and lentivirus.</s><s>Hongtao Li, Xiaojiao Wang, and other staff at the Department of Oncology of Southwest Hospital participated in managing the patients.</s><s>This work was supported by the National Key Research and Development Program (grant 2016YFC1303400), National Natural Science Foundation of China (grants 81301959 and 81520108025), and Clinical Research Project of the Southwest Hospital (SWH2016ZDCX1004).</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>AUTHOR CONTRIBUTIONS</head><p><s>C.Z., Z.Y., J.S., G.P., and C.Q. designed this trial, and C.Z., Z.Y., and C.Q. wrote the paper.</s><s>C.Z., Z. Wang, S.L., Y. Luo, H.Q., W.L., F.P., X.Z., P.B., and H.L. took responses for patient enrollment and management.</s><s>M.W., Y. Li, R.Z., Z.X., Z. Wei, and Q.Z.</s><s>conducted the experiments.</s><s>L.L. and F.W. managed all specimens.</s><s>W.C. was responsible for radiological images.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONFLICTS OF INTEREST</head><p><s>The authors declare no conflicts of interest.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Chimeric antigen receptor T cells for sustained remissions in leukemia</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Maude</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Frey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Shaw</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Aplenc</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Barrett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Bunin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Chew</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">E</forename><surname>Gonzalez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">F</forename><surname>Lacey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N. Engl. J. Med</title>
		<imprint>
			<biblScope unit="volume">371</biblScope>
			<biblScope unit="page" from="1507" to="1517" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Kochenderfer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Dudley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Kassim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Somerville</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">O</forename><surname>Carpenter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Stetler-Stevenson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">Q</forename><surname>Phan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Hughes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Sherry</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Clin. Oncol</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="540" to="549" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma</title>
		<author>
			<persName><forename type="first">N</forename><surname>Ahmed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">S</forename><surname>Brawley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hegde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Robertson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ghazi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gerken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Dakhova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ashoori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Corder</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Clin. Oncol</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="1688" to="1696" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Lamers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sleijfer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Van Steenbergen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Van Elzakker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Van Krimpen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Groot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Vulto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Den Bakker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Oosterwijk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Debets</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Gratama</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol. Ther</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="904" to="912" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">U</forename><surname>Louis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Savoldo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Dotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pule</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Yvon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">D</forename><surname>Myers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Rossig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">V</forename><surname>Russell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Diouf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Liu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="page" from="6050" to="6056" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Regression of glioblastoma after chimeric antigen receptor T-cell therapy</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Alizadeh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Starr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Weng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Wagner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Naranjo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Ostberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Blanchard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kilpatrick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Simpson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N. Engl. J. Med</title>
		<imprint>
			<biblScope unit="volume">375</biblScope>
			<biblScope unit="page" from="2561" to="2569" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Katz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Burga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Mccormack</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Mooring</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Point</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Khare</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Thorn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">F</forename><surname>Stainken</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin. Cancer Res</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="3149" to="3159" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Parkhurst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Langan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Dudley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Nathan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Feldman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Morgan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Merino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Sherry</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol. Ther</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="620" to="626" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Lamers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Willemsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Van Elzakker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Van Steenbergen-Langeveld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Broertjes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Oosterwijk-Wakka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Oosterwijk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sleijfer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Debets</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Gratama</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="page" from="72" to="82" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Immunohistochemistry of carcino-embryonic antigen in the embryo, fetus and adult</title>
		<author>
			<persName><forename type="first">M</forename><surname>Nap</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mollgard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Burtin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Fleuren</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Tumour Biol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="145" to="153" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Paths to stemness: building the ultimate antitumour T cell</title>
		<author>
			<persName><forename type="first">L</forename><surname>Gattinoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Klebanoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">P</forename><surname>Restifo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Rev. Cancer</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="671" to="684" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Davila</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Riviere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bartido</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Curran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Chung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Stefanski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Borquez-Ojeda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Olszewska</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sci. Transl. Med</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="224" to="225" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Kochenderfer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Stetler-Stevenson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">K</forename><surname>Cui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Delbrook</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Feldman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Fry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Orentas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sabatino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">N</forename><surname>Shah</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">385</biblScope>
			<biblScope unit="page" from="517" to="528" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Protein L: a novel reagent for the detection of chimeric antigen receptor (CAR) expression by flow cytometry</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Chinnasamy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Morgan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Transl. Med</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">29</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Heterogeneity of the human CD4+ T-cell population: two distinct CD4+ T-cell subsets characterized by coexpression of CD45RA and CD45RO isoforms</title>
		<author>
			<persName><forename type="first">D</forename><surname>Hamann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Baars</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hooibrink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Van Lier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">88</biblScope>
			<biblScope unit="page" from="3513" to="3521" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">CD45 isoform phenotypes of human T cells: CD4(+) CD45RA(-)RO(+) memory T cells re-acquire CD45RA without losing CD45RO</title>
		<author>
			<persName><forename type="first">L</forename><surname>Arlettaz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Barbey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Dumont-Girard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Helg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Chapuis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Roux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Roosnek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur. J. Immunol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="3987" to="3994" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Flow cytometric assessment of lymphocyte subsets, lymphoid progenitors, and hematopoietic stem cells in allogeneic stem cell grafts</title>
		<author>
			<persName><forename type="first">K</forename><surname>Theilgaard-Mönch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Raaschou-Jensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Palm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Schjødt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Heilmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Vindeløv</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Jacobsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Dickmeiss</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="1073" to="1082" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Quantitative considerations supporting the irrelevance of circulating serum CEA for the immunoscintigraphic visualization of CEA expressing carcinomas</title>
		<author>
			<persName><forename type="first">K</forename><surname>Bosslet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Steinsträsser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schwarz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">P</forename><surname>Harthus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Lüben</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Kuhlmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Sedlacek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur. J. Nucl. Med</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="523" to="528" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo</title>
		<author>
			<persName><forename type="first">T</forename><surname>Schirrmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Pecher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Gene Ther</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="390" to="398" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Chimeric antigen receptor-modified T cells for acute lymphoid leukemia</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Grupp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kalos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Barrett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Aplenc</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Porter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Rheingold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">T</forename><surname>Teachey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Chew</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hauck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Wright</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N. Engl. J. Med</title>
		<imprint>
			<biblScope unit="volume">368</biblScope>
			<biblScope unit="page" from="1509" to="1518" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Current concepts in the diagnosis and management of cytokine release syndrome</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gardner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Porter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">U</forename><surname>Louis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Ahmed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Grupp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Mackall</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">124</biblScope>
			<biblScope unit="page" from="188" to="195" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Morgan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kitano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Dudley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Laurencot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Rosenberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol. Ther</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="843" to="851" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen</title>
		<author>
			<persName><forename type="first">R</forename><surname>Bos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Van Duikeren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Morreau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Franken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">N</forename><surname>Schumacher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Haanen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Van Der Burg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Melief</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Offringa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="8446" to="8455" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells</title>
		<author>
			<persName><forename type="first">L</forename><surname>Gattinoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Finkelstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Klebanoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Antony</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Palmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Spiess</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">N</forename><surname>Hwang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wrzesinski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Heimann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Exp. Med</title>
		<imprint>
			<biblScope unit="volume">202</biblScope>
			<biblScope unit="page" from="907" to="912" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Kandalaft</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Powell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Coukos</forename><surname>Jr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Transl. Med</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">157</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo</title>
		<author>
			<persName><forename type="first">D</forename><surname>Sommermeyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hudecek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Kosasih</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Gogishvili</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Maloney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Turtle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Riddell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="492" to="500" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Turtle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Hanafi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Berger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Gooley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Cherian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hudecek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Sommermeyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Melville</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Pender</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Budiarto</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Clin. Invest</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="page" from="2123" to="2138" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Bai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Cooke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Deng</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Discov</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page">15040</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Long</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">M</forename><surname>Haso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Shern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Wanhainen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Murgai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ingaramo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Walker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Kohler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">R</forename><surname>Venkateshwara</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Med</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="581" to="590" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Ye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Poussin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Harms</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Figini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Powell</surname></persName>
		</author>
		<author>
			<persName><surname>Jr</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="page" from="696" to="706" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells</title>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">U</forename><surname>Kawalekar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>O'connor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Fraietta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Mcgettigan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Posey</surname></persName>
		</author>
		<author>
			<persName><surname>Jr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Guedan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Scholler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Keith</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunity</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="380" to="390" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">K</forename><surname>Moon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Carpenito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Kapoor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Predina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Powell</surname></persName>
		</author>
		<author>
			<persName><surname>Jr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Riley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>June</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Albelda</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin. Cancer Res</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="4719" to="4730" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements</title>
		<author>
			<persName><forename type="first">M</forename><surname>Nishino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Giobbie-Hurder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gargano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Suda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">H</forename><surname>Ramaiya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">S</forename><surname>Hodi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin. Cancer Res</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="3936" to="3943" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Wolchok</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hoos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>O'day</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Weber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Hamid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lebbé</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Binder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Bohnsack</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Nichol</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin. Cancer Res</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="7412" to="7420" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Development of endothelial-specific single inducible lentiviral vectors for genetic engineering of endothelial progenitor cells</title>
		<author>
			<persName><forename type="first">G</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Kramer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Fernandez-Ruiz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Kawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Prieto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Qian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sci. Rep</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">17166</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia</title>
		<author>
			<persName><forename type="first">M</forename><surname>Kalos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Levine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Porter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Katz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Grupp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bagg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">June</forename></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sci. Transl. Med</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="95" to="73" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
